330 related articles for article (PubMed ID: 31496821)
1. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.
Zhang Y; Zou JY; Wang Z; Wang Y
Cancer Manag Res; 2019; 11():7787-7803. PubMed ID: 31496821
[TBL] [Abstract][Full Text] [Related]
2. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
Dasari A; Sobrero A; Yao J; Yoshino T; Schelman W; Yang Z; Chien C; Kania M; Tabernero J; Eng C
Future Oncol; 2021 Aug; 17(24):3151-3162. PubMed ID: 33993740
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
[TBL] [Abstract][Full Text] [Related]
4. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies.
Wang L; Cao H; Jiang C; He W; You Y; Peng K; Jin Y; Xia L
Front Oncol; 2020; 10():587692. PubMed ID: 33282739
[TBL] [Abstract][Full Text] [Related]
5. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
[TBL] [Abstract][Full Text] [Related]
6. Fruquintinib: First Global Approval.
Shirley M
Drugs; 2018 Nov; 78(16):1757-1761. PubMed ID: 30357594
[TBL] [Abstract][Full Text] [Related]
7. Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.
Wan Y; Luo D
J Gastrointest Oncol; 2023 Feb; 14(1):450-457. PubMed ID: 36915460
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
Fusco MJ; Casak SJ; Mushti SL; Cheng J; Christmas BJ; Thompson MD; Fu W; Wang H; Yoon M; Yang Y; Moore JN; Bi Y; Nan Y; Long CE; Auth D; Rahman NA; Tang S; Pazdur R; Fashoyin-Aje LA; Kluetz PG; Lemery SJ
Clin Cancer Res; 2024 May; ():. PubMed ID: 38809262
[TBL] [Abstract][Full Text] [Related]
9. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Stucchi E; Bartolini M; Airoldi M; Fazio R; Daprà V; Mondello G; Prete MG; Puccini A; Santoro A
Expert Opin Pharmacother; 2024 Mar; 25(4):371-382. PubMed ID: 38568032
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
[TBL] [Abstract][Full Text] [Related]
11. Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer.
Patell K; Mears VL; Storandt MH; Mahipal A
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):197-205. PubMed ID: 38497279
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review.
Xu X; Yu Y; Liu M; Liang L; Liu T
Transl Cancer Res; 2022 Jan; 11(1):276-287. PubMed ID: 35261903
[TBL] [Abstract][Full Text] [Related]
13. Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer.
Liu S; Lu L; Pan F; Yang C; Liang J; Liu J; Wang J; Shen R; Xin FZ; Zhang N
Oncol Res; 2022 May; 29(1):25-31. PubMed ID: 35063062
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.
Dai Y; Sun L; Zhuang L; Zhang M; Zou Y; Yuan X; Qiu H
J Gastrointest Oncol; 2022 Apr; 13(2):722-731. PubMed ID: 35557597
[TBL] [Abstract][Full Text] [Related]
15. A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.
Jin Y; Li J; Shen L; Xu J; Zhang Y; Zhang J; Pan H; Qu X; Chen Y; Zhang Q; Li J; Sun M; Qin S
Front Oncol; 2022; 12():1044328. PubMed ID: 36505849
[TBL] [Abstract][Full Text] [Related]
16. Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.
Xu R; Qin S; Guo W; Bai Y; Deng Y; Yang L; Chen Z; Zhong H; Pan H; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Xu J; Chen D; Li W; Sun S; Yu Z; Cao P; Li J; Chen H; Wang J; Wang S; Wang H; Wang N; Zhang B; Han R; Su W; Guo X; Li J
Future Oncol; 2021 Apr; 17(11):1339-1350. PubMed ID: 33325251
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer.
Lavacchi D; Roviello G; Guidolin A; Romano S; Venturini J; Caliman E; Vannini A; Giommoni E; Pellegrini E; Brugia M; Pillozzi S; Antonuzzo L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982913
[TBL] [Abstract][Full Text] [Related]
18. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S
J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer.
Shu Y; Zheng S
Front Oncol; 2021; 11():688231. PubMed ID: 34290985
[TBL] [Abstract][Full Text] [Related]
20. Acute aortic dissection caused by fruquintinib for metastatic colorectal cancer-a case report and literature review.
Deng YY; Chen YW; Wang MX; Zhu PF; Pan SY; Jiang DY; Chen ZL; Yang L
Transl Cancer Res; 2023 Jan; 12(1):177-185. PubMed ID: 36760383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]